Gw, my interpretation of the TSC/Barron's attack is not approval, it is just reality, the attack was mounted with certain understanding of the data, the power and motive behind seems kind of obvious, but not my problem. But couple that with "bad" short term technicals = distribution.
The best data from xoma was out, they created an atmosphere of "xoma bring out the best or else" a very tough standard to beat, anything else is food for lions, especially when they were "predicting" the duel presentation winner (predesigned)a self fulfilling prophecy, attacking an overbought and overvalue stock price (all biotechs without sales ARE overvalue, they are a version of the internut, just a little less bubling).
I do not have a concern about xanelim, which is an outstanding drug achivement. And I do not consider it a "2nd tier me-too" Wall Street manipulators do!
I predict tha most probably there will be a good number of subjects that will indeed showed long responses, just for the nature of the range of impredictability of responses, some will be in the oustkirt ranges below the 3rd percentiles)"roaring back" or above the 97th
percentile "long responders".
Biogen did not mentioned HOW MANY subjects belong to the "Long term responses" I will guess 5% is their number, more than that then is VERY IMPRESSIVE and EXCELLENT.
The "long term follow up" is an strange concept, the TSC is saying "one year" that is not enough for many clinical purposes and its being use as these huge advantage. I can not grasp it yet, but the "delay" for xoma/dna is very easy to grasp compared to the "early" Biogen.
I do not know what tomorrow xoma price will be, it seems it will be further decline. |
